The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment
NCT05022186, Phase 4, Unknown, Aristotle University Of Thessaloniki
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT05022186 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 90 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Aristotle University Of Thessaloniki | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Cannabidiol Oil, Homotaurine | ClinicalTrials.gov |
| First posted | 2021-08-26 | ClinicalTrials.gov |
| Last updated | 2021-08-26 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in Mini Mental State Examination (MMSE) score | 12-24 months | ClinicalTrials.gov | |
| Primary | Changes in Montreal Cognitive Assessment (MoCA) score | 12-24 months | Screening test to assess general cognitive function | ClinicalTrials.gov |
| Primary | Changes in Functional Cognitive Assessment (FUCAS) score | 12-24 months | Measurement of daily functionality | ClinicalTrials.gov |
| Primary | Changes in Letter & Category Verbal Fluency | 12-24 months | Measurement of verbal fluency, learning, long term memory and categorization skills | ClinicalTrials.gov |
| Primary | Changes in Clinical Dementia Rating Scale score | 12-24 months | Measurement of general cognitive function | ClinicalTrials.gov |
| Primary | Changes in ADAS-COG | 12-24 months | Measurement of general cognitive function | ClinicalTrials.gov |
| Primary | Changes in Rey Auditory Verbal Learning Test | 12-24 months | Screening tool to assess verbal memory and learning | ClinicalTrials.gov |
| Primary | Changes in Rey Osterrieth Complex Figure | 12-24 months | Screening tool to assess visuospatial memory | ClinicalTrials.gov |
| Primary | Changes in Functional Rating Scale for Dementia | 12-24 months | Measurement of daily functionality | ClinicalTrials.gov |
| Primary | Changes in Trail Making Test A & B | 12-24 months | Screening tool to assess working memory and processing speed | ClinicalTrials.gov |
| Primary | Changes in Geriatric Depression Scale | 12-24 months | Screening tool to assess depressive symptoms | ClinicalTrials.gov |
| Primary | Changes in SAST | 12-24 months | Screening tool to assess anxiety | ClinicalTrials.gov |
| Primary | Changes in Beck Anxiety Inventory | 12-24 months | Screening tool to assess anxiety | ClinicalTrials.gov |
| Primary | Changes in Rivermead Behavioural Memory Test | 12-24 months | Screening tool to assess episodic memory and learning | ClinicalTrials.gov |
| Primary | Changes in STROOP Test | 12-24 months | Measurement of selective attention and cognitive flexibility | ClinicalTrials.gov |
| Primary | Changes in Symbol-Digit Test | 12-24 months | Measurement of processing speed, learning and working memory | ClinicalTrials.gov |
| Primary | Changes in BDNF | 12-24 months | Cerebrospinal Fluid Biomarker | ClinicalTrials.gov |
| Primary | Changes in MDA | 12-24 months | Cerebrospinal Fluid Biomarker | ClinicalTrials.gov |
| Primary | Changes in GFAP | 12-24 months | Cerebrospinal Fluid Biomarker | ClinicalTrials.gov |
| Primary | Changes in Tau-protein | 12-24 months | Cerebrospinal Fluid Biomarker | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)